Celltrion, Inc. (KRX:068270)

Market Cap	37.26T
Revenue (ttm)	3.56T
Net Income (ttm)	422.69B
Shares Out	214.75M
EPS (ttm)	1,947.62
PE Ratio	89.08
Forward PE	33.20
Dividend	714.29 (0.42%)
Ex-Dividend Date	Dec 27, 2024

Volume	433,026
Average Volume	428,536
Open	170,100
Previous Close	169,000
Day's Range	170,100 - 177,300
52-Week Range	152,667 - 200,952
Beta	0.08
RSI	38.10
Earnings Date	May 9, 2025

About Celltrion

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,391
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2024, Celltrion's revenue was 3.56 trillion, an increase of 63.45% compared to the previous year's 2.18 trillion. Earnings were 422.69 billion, a decrease of -21.09%.